Intraperitoneal mitoxantrone: A feasibility and pharmacokinetic study

D. Civalleri, M. O. Vannozzi, F. DeCian, G. Lunardi, M. Steinweg, I. Pastrone, M. Viale, M. Esposito

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Fractionated doses have been advocated to prevent chemoperitonitis after intraperitoneal infusion of mitoxantrone. Patients with peritoneal carcinomatosis of various origin underwent surgery, including intestinal resections, with minimal residual disease. Peritoneal mitoxantrone in 1000 ml/m 2 saline was planned on the first post-operative day in groups of four patients (5 mg/m 2 for 3 and 5 days, 7.5 mg/m 2 for 3 and 4 days, 10 mg/m 2 for 2-4 days, if possible). Due to dose-limiting myelosuppression, only one and three patients received the 7.5-mg 4-day and 10-mg 3-day regimens, respectively. A total of 20 patients were consequently treated. Neither major complications nor severe pain were observed. Pharmacokinetics were completed on the 1st day in five 5-mg and five 10-mg patients, on the 5th day in three 5-mg patients, and on the 3rd day in one 10-mg patient. On the 1st day, mean peritoneal peak concentrations of mitoxantrone resulted 1.45 ± 0.56 (range 0.48-1.9) and 1.9 ± 0.85 (range 1.27-3.13) μg/ml in the 5-mg and 10-mg patients, respectively. Mean dialysate/plasma exposure (AUC) ratio was 115. Even in patients with sutures, early post-operative fractionated intraperitoneal mitoxantrone appears feasible and safe, with a high local advantage, for up to 5 days of treatment and a maximum tolerated total dose of 20-25 mg/m 2.

Original languageEnglish
Pages (from-to)172-179
Number of pages8
JournalEuropean Journal of Surgical Oncology
Volume28
Issue number2
DOIs
Publication statusPublished - Mar 2002

Fingerprint

Mitoxantrone
Feasibility Studies
Pharmacokinetics
Parenteral Infusions
Maximum Tolerated Dose
Dialysis Solutions
Residual Neoplasm
Sutures
Area Under Curve
Carcinoma
Pain

Keywords

  • Mitoxantrone
  • Parenteral infusions
  • Peritoneal neoplasms
  • Pharmacokinetics

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Civalleri, D., Vannozzi, M. O., DeCian, F., Lunardi, G., Steinweg, M., Pastrone, I., ... Esposito, M. (2002). Intraperitoneal mitoxantrone: A feasibility and pharmacokinetic study. European Journal of Surgical Oncology, 28(2), 172-179. https://doi.org/10.1053/ejso.2001.1218

Intraperitoneal mitoxantrone : A feasibility and pharmacokinetic study. / Civalleri, D.; Vannozzi, M. O.; DeCian, F.; Lunardi, G.; Steinweg, M.; Pastrone, I.; Viale, M.; Esposito, M.

In: European Journal of Surgical Oncology, Vol. 28, No. 2, 03.2002, p. 172-179.

Research output: Contribution to journalArticle

Civalleri, D, Vannozzi, MO, DeCian, F, Lunardi, G, Steinweg, M, Pastrone, I, Viale, M & Esposito, M 2002, 'Intraperitoneal mitoxantrone: A feasibility and pharmacokinetic study', European Journal of Surgical Oncology, vol. 28, no. 2, pp. 172-179. https://doi.org/10.1053/ejso.2001.1218
Civalleri, D. ; Vannozzi, M. O. ; DeCian, F. ; Lunardi, G. ; Steinweg, M. ; Pastrone, I. ; Viale, M. ; Esposito, M. / Intraperitoneal mitoxantrone : A feasibility and pharmacokinetic study. In: European Journal of Surgical Oncology. 2002 ; Vol. 28, No. 2. pp. 172-179.
@article{ab0cca4fc3ee4c6f8e2a8a7492726868,
title = "Intraperitoneal mitoxantrone: A feasibility and pharmacokinetic study",
abstract = "Fractionated doses have been advocated to prevent chemoperitonitis after intraperitoneal infusion of mitoxantrone. Patients with peritoneal carcinomatosis of various origin underwent surgery, including intestinal resections, with minimal residual disease. Peritoneal mitoxantrone in 1000 ml/m 2 saline was planned on the first post-operative day in groups of four patients (5 mg/m 2 for 3 and 5 days, 7.5 mg/m 2 for 3 and 4 days, 10 mg/m 2 for 2-4 days, if possible). Due to dose-limiting myelosuppression, only one and three patients received the 7.5-mg 4-day and 10-mg 3-day regimens, respectively. A total of 20 patients were consequently treated. Neither major complications nor severe pain were observed. Pharmacokinetics were completed on the 1st day in five 5-mg and five 10-mg patients, on the 5th day in three 5-mg patients, and on the 3rd day in one 10-mg patient. On the 1st day, mean peritoneal peak concentrations of mitoxantrone resulted 1.45 ± 0.56 (range 0.48-1.9) and 1.9 ± 0.85 (range 1.27-3.13) μg/ml in the 5-mg and 10-mg patients, respectively. Mean dialysate/plasma exposure (AUC) ratio was 115. Even in patients with sutures, early post-operative fractionated intraperitoneal mitoxantrone appears feasible and safe, with a high local advantage, for up to 5 days of treatment and a maximum tolerated total dose of 20-25 mg/m 2.",
keywords = "Mitoxantrone, Parenteral infusions, Peritoneal neoplasms, Pharmacokinetics",
author = "D. Civalleri and Vannozzi, {M. O.} and F. DeCian and G. Lunardi and M. Steinweg and I. Pastrone and M. Viale and M. Esposito",
year = "2002",
month = "3",
doi = "10.1053/ejso.2001.1218",
language = "English",
volume = "28",
pages = "172--179",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Intraperitoneal mitoxantrone

T2 - A feasibility and pharmacokinetic study

AU - Civalleri, D.

AU - Vannozzi, M. O.

AU - DeCian, F.

AU - Lunardi, G.

AU - Steinweg, M.

AU - Pastrone, I.

AU - Viale, M.

AU - Esposito, M.

PY - 2002/3

Y1 - 2002/3

N2 - Fractionated doses have been advocated to prevent chemoperitonitis after intraperitoneal infusion of mitoxantrone. Patients with peritoneal carcinomatosis of various origin underwent surgery, including intestinal resections, with minimal residual disease. Peritoneal mitoxantrone in 1000 ml/m 2 saline was planned on the first post-operative day in groups of four patients (5 mg/m 2 for 3 and 5 days, 7.5 mg/m 2 for 3 and 4 days, 10 mg/m 2 for 2-4 days, if possible). Due to dose-limiting myelosuppression, only one and three patients received the 7.5-mg 4-day and 10-mg 3-day regimens, respectively. A total of 20 patients were consequently treated. Neither major complications nor severe pain were observed. Pharmacokinetics were completed on the 1st day in five 5-mg and five 10-mg patients, on the 5th day in three 5-mg patients, and on the 3rd day in one 10-mg patient. On the 1st day, mean peritoneal peak concentrations of mitoxantrone resulted 1.45 ± 0.56 (range 0.48-1.9) and 1.9 ± 0.85 (range 1.27-3.13) μg/ml in the 5-mg and 10-mg patients, respectively. Mean dialysate/plasma exposure (AUC) ratio was 115. Even in patients with sutures, early post-operative fractionated intraperitoneal mitoxantrone appears feasible and safe, with a high local advantage, for up to 5 days of treatment and a maximum tolerated total dose of 20-25 mg/m 2.

AB - Fractionated doses have been advocated to prevent chemoperitonitis after intraperitoneal infusion of mitoxantrone. Patients with peritoneal carcinomatosis of various origin underwent surgery, including intestinal resections, with minimal residual disease. Peritoneal mitoxantrone in 1000 ml/m 2 saline was planned on the first post-operative day in groups of four patients (5 mg/m 2 for 3 and 5 days, 7.5 mg/m 2 for 3 and 4 days, 10 mg/m 2 for 2-4 days, if possible). Due to dose-limiting myelosuppression, only one and three patients received the 7.5-mg 4-day and 10-mg 3-day regimens, respectively. A total of 20 patients were consequently treated. Neither major complications nor severe pain were observed. Pharmacokinetics were completed on the 1st day in five 5-mg and five 10-mg patients, on the 5th day in three 5-mg patients, and on the 3rd day in one 10-mg patient. On the 1st day, mean peritoneal peak concentrations of mitoxantrone resulted 1.45 ± 0.56 (range 0.48-1.9) and 1.9 ± 0.85 (range 1.27-3.13) μg/ml in the 5-mg and 10-mg patients, respectively. Mean dialysate/plasma exposure (AUC) ratio was 115. Even in patients with sutures, early post-operative fractionated intraperitoneal mitoxantrone appears feasible and safe, with a high local advantage, for up to 5 days of treatment and a maximum tolerated total dose of 20-25 mg/m 2.

KW - Mitoxantrone

KW - Parenteral infusions

KW - Peritoneal neoplasms

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0036490589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036490589&partnerID=8YFLogxK

U2 - 10.1053/ejso.2001.1218

DO - 10.1053/ejso.2001.1218

M3 - Article

C2 - 11884053

AN - SCOPUS:0036490589

VL - 28

SP - 172

EP - 179

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 2

ER -